

# Thomas S Harrison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8913642/publications.pdf>

Version: 2024-02-01

175  
papers

15,191  
citations

25034

57  
h-index

19749

117  
g-index

183  
all docs

183  
docs citations

183  
times ranked

9270  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid urine-based screening tests increase the yield of same-day tuberculosis diagnoses among patients living with advanced HIV disease. <i>Aids</i> , 2022, Publish Ahead of Print, .	2.2	2
2	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. <i>New England Journal of Medicine</i> , 2022, 386, 1109-1120.	27.0	119
3	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	25
4	Tackling the emerging threat of antifungal resistance to human health. <i>Nature Reviews Microbiology</i> , 2022, 20, 557-571.	28.6	311
5	Prior Pulmonary Tuberculosis Is a Risk Factor for Asymptomatic Cryptococcal Antigenemia in a Cohort of Adults With Advanced Human Immunodeficiency Virus Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
6	Decision making in a clinical trial for a life-threatening illness: Therapeutic expectation, not misconception. <i>Social Science and Medicine</i> , 2022, 305, 115082.	3.8	5
7	Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana. <i>Biomedicine</i> , 2022, 10, 1399.	3.2	3
8	Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1365-1373.	9.1	13
9	Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1584-1586.	2.4	6
10	Presentations and outcomes of central nervous system TB in a UK cohort: The high burden of neurological morbidity. <i>Journal of Infection</i> , 2021, 82, 90-97.	3.3	12
11	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. <i>Clinical Infectious Diseases</i> , 2021, 72, 1268-1278.	5.8	51
12	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 16-18.	9.1	18
13	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab066.	0.9	6
14	The Lived Experience Of Participants in an African Randomised trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. <i>BMJ Open</i> , 2021, 11, e039191.	1.9	7
15	Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009376.	3.0	8
16	Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy- Naïve and Experienced Patients in Sub-Saharan Africa. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab397.	0.9	9
17	Neurological deterioration in a patient with HIV-associated cryptococcal meningitis initially improving on antifungal treatment: a case report of coincidental racemose neurocysticercosis. <i>BMC Infectious Diseases</i> , 2021, 21, 724.	2.9	1
18	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1266.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Combination Therapy for HIV-Associated Cryptococcal Meningitisâ€”A Success Story. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 1098.	3.5	3
20	Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1652-1657.	5.8	7
21	One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. <i>Clinical Infectious Diseases</i> , 2020, 70, 521-524.	5.8	13
22	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 26-29.	5.8	13
23	Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. <i>Clinical Infectious Diseases</i> , 2020, 70, 1683-1690.	5.8	38
24	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
25	Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana. <i>Medicine (United States)</i> , 2020, 99, e22606.	1.0	4
26	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. <i>Aids</i> , 2020, 34, 1425-1428.	2.2	9
27	Determine TB-LAM point-of-care tuberculosis assay predicts poor outcomes in outpatients during their first year of antiretroviral therapy in South Africa. <i>BMC Infectious Diseases</i> , 2020, 20, 555.	2.9	3
28	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	3.9	10
29	HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana. <i>Viruses</i> , 2020, 12, 1404.	3.3	2
30	Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	19
31	Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme. <i>International Journal of Infectious Diseases</i> , 2020, 95, 459-461.	3.3	10
32	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa489.	0.9	12
33	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virusâ€”associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 393-401.	5.8	62
34	Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naïve Human Immunodeficiency Virusâ€”infected Adults With CD4 Cell Counts <100/µL: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019, 68, 688-698.	5.8	38
35	Understanding Causal Pathways in Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2019, 219, 344-346.	4.0	8
36	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16

#	ARTICLE	IF	CITATIONS
37	Reply to Rajasingham and Boulware. <i>Clinical Infectious Diseases</i> , 2019, 69, 732-735.	5.8	2
38	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2019, 69, 588-595.	5.8	18
39	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019, 9, e026288.	1.9	6
40	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019, 10, .	4.1	44
41	Low-cerebrospinal fluid white cell counts and mortality in HIV-associated pneumococcal meningitis. <i>Aids</i> , 2019, 33, 1539-1541.	2.2	1
42	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e143-e147.	9.1	63
43	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 999-1014.	8.2	112
44	Recent advances in managing HIV-associated cryptococcal meningitis. <i>F1000Research</i> , 2019, 8, 743.	1.6	11
45	Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 1030.	0.9	33
46	Long term mortality and disability in Cryptococcal Meningitis: a systematic literature review.. <i>Clinical Infectious Diseases</i> , 2018, 66, 1122-1132.	5.8	53
47	Advances in the diagnosis and treatment of fungal infections of the CNS. <i>Lancet Neurology</i> , The, 2018, 17, 362-372.	10.2	93
48	Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 724-731.	3.0	17
49	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. <i>New England Journal of Medicine</i> , 2018, 378, 1004-1017.	27.0	296
50	Poor specificity of urinary cryptococcal antigen testing. <i>HIV Medicine</i> , 2018, 19, e47-e48.	2.2	3
51	High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 686-692.	5.8	76
52	Cryptococcal meningitis in apparently immunocompetent patients: association with idiopathic CD4+ lymphopenia. <i>Practical Neurology</i> , 2018, 18, 166-169.	1.1	6
53	The treatment of a pregnant HIV positive patient with cryptococcal meningitis in Malawi. Case report and review of treatment options. <i>Medical Mycology Case Reports</i> , 2018, 19, 9-12.	1.3	4
54	Effect of oral fluconazole 1200mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis. <i>Aids</i> , 2018, 32, 2259-2261.	2.2	4

#	ARTICLE	IF	CITATIONS
55	AMBIsome Therapy Induction Optimisation (AMBITON): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> , 2018, 19, 649.	1.6	41
56	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. <i>MBio</i> , 2018, 9, .	4.1	5
57	Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report. <i>BMC Infectious Diseases</i> , 2018, 18, 520.	2.9	14
58	Brief Report: Point of Care Cryptococcal Antigen Screening: Pipetting Finger-Prick Blood Improves Performance of Immunomycologics Lateral Flow Assay. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 574-578.	2.1	19
59	Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. <i>Frontiers in Microbiology</i> , 2018, 9, 409.	3.5	46
60	The <i>Cryptococcus neoformans</i> Titan cell is an inducible and regulated morphotype underlying pathogenesis. <i>PLoS Pathogens</i> , 2018, 14, e1006978.	4.7	137
61	The Case for Adopting the “Species Complex” Nomenclature for the Etiologic Agents of Cryptococcosis. <i>MSphere</i> , 2017, 2, .	2.9	274
62	A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. <i>G3: Genes, Genomes, Genetics</i> , 2017, 7, 1165-1176.	1.8	79
63	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
64	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008–2014. <i>Journal of Infection</i> , 2017, 74, 260-271.	3.3	15
65	Fungal infections in HIV/AIDS. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e334-e343.	9.1	327
66	Cryptococcal meningitis. <i>British Journal of Hospital Medicine</i> (London, England: 2005), 2017, 78, C125-C127.	0.5	7
67	Itraconazole and antiretroviral therapy: strategies for empirical dosing – Author's reply. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1123-1124.	9.1	1
68	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	37
69	Tracing Genetic Exchange and Biogeography of <i>Cryptococcus neoformans</i> var. <i>grubii</i> at the Global Population Level. <i>Genetics</i> , 2017, 207, 327-346.	2.9	105
70	Genomic epidemiology of <i>Cryptococcus</i> yeasts identifies adaptation to environmental niches underpinning infection across an African HIV/AIDS cohort. <i>Molecular Ecology</i> , 2017, 26, 1991-2005.	3.9	59
71	Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. <i>Nature Reviews Neurology</i> , 2017, 13, 13-24.	10.1	344
72	The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies. <i>PLoS ONE</i> , 2017, 12, e0171917.	2.5	21

#	ARTICLE	IF	CITATIONS
73	Cryptococcal meningitis: A neglected NTD?. PLoS Neglected Tropical Diseases, 2017, 11, e0005575.	3.0	47
74	Immune correlates of HIV-associated cryptococcal meningitis. PLoS Pathogens, 2017, 13, e1006207.	4.7	19
75	A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease, 2016, 20, 832-838.	1.2	41
76	XDR-TB transmission in London: Case management and contact tracing investigation assisted by early whole genome sequencing. Journal of Infection, 2016, 73, 210-218.	3.3	28
77	Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. Clinical Infectious Diseases, 2016, 62, 581-587.	5.8	99
78	Forgotten but not gone: HIV-associated cryptococcal meningitis. Lancet Infectious Diseases, The, 2016, 16, 756-758.	9.1	14
79	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. Trials, 2015, 16, 276.	1.6	22
80	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. PLoS Neglected Tropical Diseases, 2015, 9, e0003847.	3.0	94
81	Clinical Application of Whole-Genome Sequencing To Inform Treatment for Multidrug-Resistant Tuberculosis Cases. Journal of Clinical Microbiology, 2015, 53, 1473-1483.	3.9	89
82	Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis. Journal of Infection, 2015, 70, 668-675.	3.3	39
83	Cerebrospinal Fluid Cytokine Profiles Predict Risk of Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis. PLoS Pathogens, 2015, 11, e1004754.	4.7	117
84	Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet, The, 2015, 385, 2173-2182.	13.7	197
85	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2015, 59, 7224-7231.	3.2	99
86	Cryptococcal antigen screening in HIV-infected adults - let's get straight to the point-of-care. Aids, 2015, 30, 1.	2.2	7
87	A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi. PLoS ONE, 2014, 9, e110285.	2.5	56
88	Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days. MBio, 2014, 5, e00725-13.	4.1	23
89	Cryptococcus neoformans Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis. Journal of Infectious Diseases, 2014, 209, 74-82.	4.0	90
90	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. Clinical Infectious Diseases, 2014, 58, 736-745.	5.8	299

#	ARTICLE	IF	CITATIONS
91	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 493-500.	5.8	10
92	Access to antifungal medicines in resource-poor countries â€œ Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 371.	9.1	4
93	Systemic fungal infections. <i>Medicine</i> , 2014, 42, 26-30.	0.4	5
94	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. <i>New England Journal of Medicine</i> , 2014, 371, 1599-1608.	27.0	383
95	Vitamin D deficiency in HIV-infected South Africans: Common, and not associated with susceptibility, immune response, or outcome in HIV-associated cryptococcal meningitis. <i>International Journal of Infectious Diseases</i> , 2014, 21, 284.	3.3	1
96	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2000-2008.	8.2	130
97	Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2793-2800.	3.2	52
98	Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 629-637.	9.1	151
99	The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. <i>Journal of Infection</i> , 2013, 66, 75-79.	3.3	27
100	The Phenotype of the Cryptococcus-Specific CD4+ Memory T-Cell Response Is Associated With Disease Severity and Outcome in HIV-Associated Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2013, 207, 1817-1828.	4.0	113
101	Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 2013, 208, 351-361.	4.0	47
102	Cryptococcal immune reconstitution inflammatory syndrome. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 26-34.	3.1	60
103	Evaluation of a pro-active strategy for managing tuberculosisâ€œHIV co-infection in a UK tertiary care setting. <i>International Journal of STD and AIDS</i> , 2013, 24, 263-268.	1.1	2
104	Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2435-2444.	3.0	121
105	Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa. <i>PLoS ONE</i> , 2013, 8, e69288.	2.5	112
106	A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi. <i>PLoS ONE</i> , 2013, 8, e67311.	2.5	62
107	Reply to Lee and Newton. <i>Clinical Infectious Diseases</i> , 2012, 55, 1745-1746.	5.8	0
108	Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4471-4473.	3.2	30



#	ARTICLE	IF	CITATIONS
109	Adjunctive interferon- $\gamma$ immunotherapy for the treatment of HIV-associated cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1105-1113.	2.2	238
110	A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1363-1370.	2.2	73
111	Immunotherapy for fungal infections. <i>Current Opinion in Microbiology</i> , 2012, 15, 434-439.	5.1	26
112	Cryptococcal Antigen Screening and Preemptive Therapy in Patients Initiating Antiretroviral Therapy in Resource-Limited Settings. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 374-379.	1.2	52
113	Early Clinical and Subclinical Visual Evoked Potential and Humphrey's Visual Field Defects in Cryptococcal Meningitis. <i>PLoS ONE</i> , 2012, 7, e52895.	2.5	20
114	Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2012, 54, 121-128.	5.8	127
115	Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. <i>Journal of Infection</i> , 2012, 64, 76-81.	3.3	69
116	Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine From Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2011, 53, 1019-1023.	5.8	266
117	Prevention of AIDS-associated cryptococcosis in resource-poor areas. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 892-894.	9.1	3
118	Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts - time to implement in South Africa?. <i>South African Medical Journal</i> , 2011, 101, 232.	0.6	20
119	Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. <i>Journal of Infection</i> , 2011, 63, 484-486.	3.3	15
120	Low Diversity <i>Cryptococcus neoformans</i> Variety <i>grubii</i> Multilocus Sequence Types from Thailand Are Consistent with an Ancestral African Origin. <i>PLoS Pathogens</i> , 2011, 7, e1001343.	4.7	74
121	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1815-1820.	3.0	80
122	Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?. <i>Aids</i> , 2010, 24, 612-614.	2.2	23
123	Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. <i>Aids</i> , 2010, 24, 1233-1235.	2.2	24
124	Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. <i>Journal of Infection</i> , 2010, 60, 496-498.	3.3	42
125	Positive predictive value of the UK clinical case definition for H1N1/09 (‘swine’™) influenza. <i>Journal of Infection</i> , 2010, 60, 405-407.	3.3	5
126	Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. <i>BMC Infectious Diseases</i> , 2010, 10, 67.	2.9	222



#	ARTICLE	IF	CITATIONS
127	Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: The role of inadequate secondary prophylaxis. <i>South African Medical Journal</i> , 2010, 100, 378.	0.6	40
128	Cryptococcal Antigen Screening for Patients Initiating Antiretroviral Therapy: Time for Action. <i>Clinical Infectious Diseases</i> , 2010, 51, 1463-1465.	5.8	35
129	Should Antiretroviral Therapy Be Delayed for 10 Weeks for Patients Treated with Fluconazole for Cryptococcal Meningitis?. <i>Clinical Infectious Diseases</i> , 2010, 51, 986-987.	5.8	7
130	Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. <i>Aids</i> , 2010, 24, 405-410.	2.2	64
131	Cerebrospinal Fluid HIV-1 Viral Load During Treatment of Cryptococcal Meningitis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 668-669.	2.1	5
132	<i>Cryptococcus: Spectrum of Disease and Treatment.</i> , 2010, , 145-165.		0
133	Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 199-202.	1.3	11
134	Combination Flucytosine and High-Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi. <i>Clinical Infectious Diseases</i> , 2010, 50, 338-344.	5.8	166
135	Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. <i>International Journal of Infectious Diseases</i> , 2010, 14, e310-e312.	3.3	28
136	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2010, 50, 291-322.	5.8	2,195
137	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 702-709.	5.8	201
138	The burden of HIV-associated cryptococcal disease. <i>Aids</i> , 2009, 23, 531-532.	2.2	27
139	Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis: A Prospective Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 51, 130-134.	2.1	162
140	Reducing Mortality Associated with Opportunistic Infections among Patients with Advanced HIV Infection in Sub-Saharan Africa: Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009, 49, 812-813.	5.8	3
141	Association of Mannose-Binding Lectin Deficiency with Acute Invasive Aspergillosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1486-1491.	5.8	75
142	Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa. <i>Clinical Infectious Diseases</i> , 2009, 48, 856-862.	5.8	283
143	Amphotericin B plus Fluconazole for HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1784-1786.	5.8	5
144	Systemic fungal infections. <i>Medicine</i> , 2009, 37, 660-664.	0.4	1

#	ARTICLE	IF	CITATIONS
145	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. <i>Aids</i> , 2009, 23, 1182-1183.	2.2	83
146	Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. <i>Aids</i> , 2009, 23, 701-706.	2.2	168
147	High-Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV-Infected Patients: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 123-130.	5.8	238
148	Reply to Pasqualotto. <i>Clinical Infectious Diseases</i> , 2008, 47, 1110-1111.	5.8	2
149	Pulmonary Cryptococcosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 141-150.	2.1	81
150	Dose Response Effect of High-Dose Fluconazole for HIV-Associated Cryptococcal Meningitis in Southwestern Uganda. <i>Clinical Infectious Diseases</i> , 2008, 47, 1556-1561.	5.8	180
151	Managing cryptococcosis in the immunocompromised host. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 596-603.	3.1	47
152	Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1038-1042.	3.2	57
153	Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naïve or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole. <i>Clinical Infectious Diseases</i> , 2007, 45, 76-80.	5.8	261
154	HIV-associated cryptococcal meningitis. <i>Aids</i> , 2007, 21, 2119-2129.	2.2	213
155	Immune dysfunction in HIV-seronegative, <i>Cryptococcus gattii</i> meningitis. <i>Journal of Infection</i> , 2007, 54, e165-e168.	3.3	37
156	Role of Capsule and Interleukin-6 in Long-Term Immune Control of <i>Cryptococcus neoformans</i> Infection by Specifically Activated Human Peripheral Blood Mononuclear Cells. <i>Infection and Immunity</i> , 2006, 74, 5302-5310.	2.2	28
157	Symptomatic Relapse of HIV-Associated Cryptococcal Meningitis after Initial Fluconazole Monotherapy: The Role of Fluconazole Resistance and Immune Reconstitution. <i>Clinical Infectious Diseases</i> , 2006, 43, 1069-1073.	5.8	210
158	Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. <i>Journal of Infection</i> , 2005, 51, e221-e224.	3.3	56
159	Baseline Correlation and Comparative Kinetics of Cerebrospinal Fluid Colony-Forming Unit Counts and Antigen Titers in Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2005, 192, 681-684.	4.0	59
160	Correspondence of In Vitro and In Vivo Fluconazole Dose-Response Curves for <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3297-3301.	3.2	21
161	IFN- $\gamma$ at the Site of Infection Determines Rate of Clearance of Infection in Cryptococcal Meningitis. <i>Journal of Immunology</i> , 2005, 174, 1746-1750.	0.8	150
162	Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 530-531.	9.1	57

#	ARTICLE	IF	CITATIONS
163	Systemic fungal infections. Medicine, 2005, 33, 116-119.	0.4	2
164	Cryptococcal meningitis. British Medical Bulletin, 2004, 72, 99-118.	6.9	286
165	Intrathecal Production and Secretion of Vascular Endothelial Growth Factor during Cryptococcal Meningitis. Journal of Infectious Diseases, 2004, 190, 1310-1317.	4.0	32
166	Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet, The, 2004, 363, 1764-1767.	13.7	432
167	Dengue Hemorrhagic Fever with Fulminant Hepatic Failure in an Immigrant Returning to Bangladesh. Clinical Infectious Diseases, 2003, 37, e1-e4.	5.8	33
168	Cryptococcus neoformans and Cryptococcosis. Journal of Infection, 2000, 41, 12-17.	3.3	29
169	<i>Cryptococcus neoformans</i>Resides in an Acidic Phagolysosome of Human Macrophages. Infection and Immunity, 1999, 67, 885-890.	2.2	214
170	Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation.. Journal of Clinical Investigation, 1997, 100, 1640-1646.	8.2	116
171	Co-prevalent infections in adults with HIV-associated cryptococcal meningitis are associated with an increased risk of death: a nested analysis of the Advancing Cryptococcal meningitis Treatment for Africa (ACTA) cohort. Wellcome Open Research, 0, 6, 19.	1.8	0
172	Cryptococcosis in Asia. , 0, , 287-297.		3
173	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries. , 0, , 565-584.		1
174	Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study. Wellcome Open Research, 0, 4, 83.	1.8	0
175	Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study. Wellcome Open Research, 0, 4, 83.	1.8	0